Search Results
Your search for ,WHo matches 20197 pages
Showing 1901 - 1950Data Analysis of Young-Onset Lung Cancer Reveals Key Differences Compared With the Disease in Older Adults
Lung cancer, both small cell and non–small cell, is the second most common cancer in both men and women in the United States, with about 238,340 new cases diagnosed each year, and the leading cause of cancer-related mortality, accounting for more than 127,000 deaths annually.1 Lung cancer in...
Incremental Gains Toward Better Outcomes in Small Cell Lung Cancer
Novel treatments beyond the current chemoimmunotherapies are offering more treatment options in small cell lung cancer (SCLC), though real breakthroughs remain elusive, according to Ticiana Leal, MD, Associate Professor in the Department of Hematology and Medical Oncology, Emory University School...
First-in-Class Bifunctional Antibody Plus Pembrolizumab Shows Activity in Head and Neck Squamous Cell Carcinoma
The first-in-class bifunctional antibody BCA101—which inhibits both the epidermal growth factor receptor (EGFR) and transforming growth factor-beta (TGF-β)—given with the immune checkpoint inhibitor pembrolizumab, is showing activity and tolerability in recurrent or metastatic head and neck...
More on Treatments Under Study in NSCLC From ASCO 2023
Two phase III trials presented at the 2023 ASCO Annual Meeting explored treatments under study for patients with non–small cell lung cancer (NSCLC). In an exploratory analysis of the CodeBreaK 200 trial, the KRAS inhibitor sotorasib was compared with docetaxel chemotherapy in subsets of patients...
Wei Wu, MD, PhD, on Lung Cancer: Deep Learning as a Tool for Identifying Drug-Tolerant Persister Cells
Wei Wu, MD, PhD, of the University of California, San Francisco, discusses new findings that suggest his team’s deep learning neural network model may be able to identify subpopulations of patients with lung cancer who have YAP1-activated tumors and drug-tolerant persister cells. These patients may ...
More on Melanoma From ASCO 2023: Focus on Two Different Treatment Strategies
In patients with melanoma who are undergoing neoadjuvant therapy with immune checkpoint blockade, response to treatment may guide the intensity of additional treatment, according to a retrospective analysis of two major trials presented by Irene L.M. Reijers, an MD/PhD candidate in the Christian...
More on Multiple Myeloma From ASCO 2023: Focus on Bispecific Antibodies
Two new bispecific antibodies—teclistamab and talquetamab—have been shown to be active in relapsed or refractory multiple myeloma when used in combination, including in patients with extramedullary disease, without compounding toxicity. Results of two clinical trials with these two agents were...
Study Shows Benefit With Addition of Tumor Treating Fields Therapy in Metastatic Non–Small Cell Lung Cancer
Tumor treating fields (TTF) therapy in combination with immune checkpoint inhibition improved overall survival in the pretreated, primarily immunotherapy-naive setting in metastatic non–small cell lung cancer (NSCLC), according to findings from the phase III LUNAR study. These results were...
AI-Based Tool Aids in Diagnosis of Cervical Cancers and Precancers
A new artificial intelligence (AI)-based diagnostic tool for colposcopy examinations may improve the accuracy of diagnosing cancerous and precancerous cervical lesions, including cervical intraepithelial neoplasia (CIN), according to a retrospective validation study presented at the 2023 ASCO...
Expert Point of View: Peter Paul Yu, MD, FACP, FASCO
ASCO EXPERT Peter Paul Yu, MD, FACP, FASCO, commented on the implications of the study presented by Zhao et al. Dr. Yu is Physician-in-Chief at the Hartford HealthCare Cancer Institute. “Tumor microbiome studies are at the cutting edge of precision medicine metabolomics,” Dr. Yu stated....
Gut Microbiome Differs in Responders and Nonresponders to Immune Checkpoint Inhibitors in Patients With HCC
In patients with advanced hepatocellular carcinoma (HCC), gut microbiome characteristics differed between those who had durable responses to immunotherapy and those who did not, according to a retrospective study presented at the 2023 ASCO Breakthrough meeting.1 The presence of Clostridium...
Expert Point of View: Peter Paul Yu, MD, FACP, FASCO
ASCO EXPERT Peter Paul Yu, MD, FACP, FASCO, commented on these GALAXY trial findings. He noted the results of this current study and others planned will establish the role of circulating tumor DNA (ctDNA) monitoring for risk of recurrence and guidance for adjuvant therapy. Dr. Yu is...
Predicting Recurrence in Colorectal Cancer Using Postoperative Circulating Tumor DNA Dynamics
Postoperative molecular residual disease detected by circulating tumor DNA (ctDNA) at 4 weeks after resection has emerged as the strongest prognostic risk factor for disease-free survival in patients with resected colorectal cancer. This finding was observed regardless of BRAF V600E status and...
Study Shows Exercise May Improve Sexual Function in Men With Prostate Cancer
It seems that exercise is good for almost everything, including prostate cancer. In fact, exercise had a positive effect on sexual function and enjoyment in men with prostate cancer, according to a recent study presented at the 2023 ASCO Breakthrough meeting by lead study author Daniel Galvão, PhD, ...
Crystal S. Denlinger, MD, FACP, Named New Chief Executive Officer of NCCN
The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading academic cancer centers—announced Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer (CEO). Dr. Denlinger—who is currently NCCN’s Senior Vice President, Chief Scientific Officer—will lead the ...
Rising After Struggle: Surviving My First ASCO Breakthrough in Japan
After a year of hard work preparing a strong abstract for the prestigious 2023 ASCO Annual Meeting, I finally received an acceptance letter from the scientific committee. I was overjoyed to see the efforts of our multinational team being rewarded. A few moments later, I received the decision...
A Near-Future Look at Medicine When AI Has a Mind of Its Own
“Dr. Hope Kestrel was the only person who knew the patient in Room 132 wasn’t responding to the algorithm-selected treatment. She shuffled forward in the hospital security line, wanting to ger her day started already yet dreading how she’d tell her patient the unexpected and devastating news.” So...
Thomas J. Herzog, MD, Takes Office as President of the GOG Foundation, Inc
Thomas J. Herzog, MD, took office as President of the GOG Foundation (GOG-F, formerly the Gynecologic Oncology Group), Inc, on July 20, 2023, at the NRG Oncology Summer Meeting. Former GOG-F President, Larry J. Copeland, MD, passed the presidential gavel to Dr. Herzog at the GOG-F Board of...
Benjamin Besse, MD, PhD, Chooses a Career in Medicine Over Music
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Benjamin Besse, MD, PhD, Professor of Medical Oncology at Paris-Saclay University, Orsay, France, and lung cancer specialist at Gustave Roussy Cancer Campus, Villejuif. Currently, Dr....
There’s an App for That: Digital Health Solutions for Treating Insomnia in Cancer Survivors
Guest Editor’s Note: Insomnia is common in patients with cancer and cancer survivors, and it has significant negative consequences. Cognitive behavior therapy for insomnia (CBT-I) is an effective approach for managing insomnia but is not easily available to many patients. In this installment of The ...
Jesse M. Ehrenfeld, MD, MPH, Inaugurated as President of the AMA
Jesse M. Ehrenfeld, MD, MPH, was sworn in as the 178th President of the American Medical Association (AMA), the nation’s premier physician organization, on June 13, 2023. At his inauguration, Dr. Ehrenfeld spoke about health inequities and injustices: “The AMA has made tremendous strides in recent ...
Trifluridine/Tipiracil Plus Bevacizumab in Previously Treated Metastatic Colorectal Cancer
On August 2, 2023, the fixed combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, was approved for use with bevacizumab for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based...
Expert Point of View: Cathy Eng, MD, FACP, FASCO
Cathy Eng, MD, FACP, FASCO, the David H. Johnson Chair in Surgical and Medical Oncology, Professor of Medicine, Hematology and Oncology, Co-Director of GI Oncology and Co-Leader of the Gastrointestinal Cancer Research Program at Vanderbilt-Ingram Cancer Center, Nashville, commented that the...
LEAP-017: No Significant Benefit for Lenvatinib Plus Pembrolizumab in Non–MSI-H/dMMR Metastatic Colorectal Cancer
In the final analysis of the phase III LEAP-017 study, the combination of lenvatinib plus pembrolizumab failed to improve outcomes over the standard of care in previously treated patients with metastatic colorectal cancer that lacked high microsatellite instability or mismatch repair deficiency...
Selinexor Shows Activity as Maintenance Therapy for TP53 Wild-Type Endometrial Cancer in Phase III Trial
Long-term follow-up of selinexor maintenance therapy has demonstrated promising efficacy in patients with TP53 wild-type endometrial cancer, according to data presented during the ASCO Plenary Series: July 2023 Session.1 Selinexor is a selective inhibitor of nuclear export (SINE) approved for use...
Cytotoxic and Immune-Stimulatory Gene Therapy for Adults With Primary High-Grade Glioma
In a single-center, phase I, first-in-human trial reported in The Lancet Oncology, Yoshie Umemura, MD, and colleagues investigated treatment with the combination of two adenoviral vectors expressing HSV1-TK (Ad-hCMV-TK) and Flt3L (Ad-hCMV-Flt3L) in adults with primary high-grade glioma. As stated...
Risk Factors for Incident Heart Failure Among Cancer Survivors Aged 18 to 39
In a study reported in a research letter in JACC: CardioOncology, Hibler et al found that survivors of young adult cancers who were exposed to anthracyclines were at an increased risk of subsequent diagnosis of heart failure. Study Details The study involved electronic health record data from the...
Radiation Exposure From Medical Imaging in Pediatric Patients With Down Syndrome
Pediatric patients with Down syndrome may undergo almost 10 times as many medical imaging examinations as other pediatric patients, potentially exposing them to more ionizing radiation, according to a recent study published by Marlow et al in PLOS ONE. Background Ionizing radiation is present in...
Vitamin C and D Supplements for Patients With AML Undergoing Intensive Chemotherapy
Patients with acute myeloid leukemia (AML) who received vitamin C and D supplements during intensive chemotherapy had lower rates of complications such as infections, bleeding, and inflammation compared with patients who did not receive the supplements, according to a recent study published by...
ASCO Participates in President’s Cancer Panel Event
ASCO joined the President’s Cancer Panel on September 7, 2023, to highlight the numerous ways ASCO is working to advance the National Cancer Plan and achieve President Biden’s Cancer Moonshot goal of “ending cancer as we know it.” This all-day, virtual event was the first public meeting in support...
Nicholas J. Short, MD on Acute Lymphoblastic Leukemia: Phase II Findings on Mini-HCVD, Inotuzumab, and Blinatumomab
Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses new data on improved outcomes in patients with relapsed or refractory acute lymphoblastic leukemia who received the combination of mini-HCVD and reduced-dose inotuzumab and then blinatumomab in sequence. In...
Efficacy of the 9-Valent HPV Vaccine: 10-Year Follow-up
New 10-year follow-up data were published by Restrepo et al in Pediatrics on girls and boys who received a three-dose regimen of the 9-valent human papillomavirus (HPV) vaccine between the ages of 9 and 15. The long-term follow-up study was conducted from 2009 through 2021 across 13 countries and 5 ...
Enhanced Recovery Program May Be Effective at Reducing Opioid Use After Pancreatic Cancer Surgery
Improving hospital care pathways may help reduce inpatient opioid use by 50% and cut the median opioid prescription volumes at discharge to zero in patients undergoing pancreatic cancer surgery, according to a recent study published by Boyev et al in JAMA Surgery. The new findings could help reduce ...
SNMMI Provides New Consensus Statement on LuPSMA Therapy
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has provided standardized guidance on the selection and management of patients receiving lutetium-177–labeled PSMA-617 (LuPSMA) radionuclide therapy for metastatic castration-resistant prostate cancer, according to a new consensus...
Allogeneic HCT Outcomes in Patients With MDS and High-Risk Genetics
In a genetic analysis from the Blood and Marrow Transplant Clinical Trials Network 1102 Study reported in the Journal of Clinical Oncology, Versluis et al found that allogeneic hematopoietic cell transplantation (HCT) improved overall survival compared with non-HCT treatment in patients with...
Phase III Trial Reports Chemoimmunotherapy Is Superior to Chemotherapy Alone in Malignant Pleural Mesothelioma
Patients with malignant pleural mesothelioma who were treated with a chemoimmunotherapy regimen containing the immune checkpoint inhibitor pembrolizumab experienced significantly improved overall survival compared with those treated with chemotherapy alone, with acceptable tolerability, according...
Examining Disparities in Endometrial Cancer Outcomes Among Black Patients
Black patients with stage IA low-grade endometrioid endometrial carcinoma may be less likely to undergo a hysterectomy and survive their cancer than White patients with the same type of cancer, according to a recent study published by Taylor et al in Gynecologic Oncology. Background “We’ve known...
23andMe Granted FDA 510(k) Clearance to Report Additional BRCA Variants
23andMe has announced that the company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report. The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be ...
Statins May Be Linked to Lower Risk of Colorectal Cancer in Patients With Ulcerative Colitis
Cholesterol-lowering statins may reduce colorectal cancer incidence and mortality in patients with ulcerative colitis, according to a recent study published by Sun et al in eClinicalMedicine. The findings also suggested that statin use may be associated with a lower risk of all-cause mortality in...
Strategies to Predict Immunotherapy Benefit Among Patients With Advanced Colorectal Cancer
Researchers have identified new strategies to help physicians predict which patients with advanced colorectal cancer may benefit from immunotherapy, according to a recent study published by Saberzadeh-Ardestani et al in Clinical Cancer Research. The findings demonstrate the potential of using...
New Data on a Response Biomarker for Dovitinib in Patients With RCC
A new report published by Knudsen et al in PLOS ONE focused on the clinical validation of a drug response predictor (DRP) biomarker algorithm for dovitinib, a receptor tyrosine kinase inhibitor of VEGFR1–3, PDGFR, FGFR1/3, c-KIT, FLT3, and topoisomerase 1 and 2. Data showed that the DRP-dovitinib...
Improving Nutrition Guidance May Optimize Fertility Treatments for Female Cancer Survivors
Researchers have identified potential strategies to promote healthy dietary habits in female cancer survivors with fertility challenges, according to a recent study published by Klobodu et al in Integrative Cancer Therapies. Background Cancer may increase the risk of infertility in young female...
Updates on Cancer Therapies Under Study From 2023 ASCO Breakthrough
Presented here are some brief summaries of novel therapies under study from the 2023 ASCO Breakthrough meeting in Yokohama, Japan. The subjects range from new observations about a HER2-directed bispecific antibody and systemic treatment of gastric cancer to an option for treating hand-foot syndrome ...
Immunochemotherapy Triplet in Patients With Advanced Nonsquamous NSCLC and Untreated Brain Metastases
In a Spanish phase II study (Atezo-Brain; GECP17/05) reported in the Journal of Clinical Oncology, Ernest Nadal, MD, PhD, and colleagues investigated the activity of the combination of atezolizumab with chemotherapy in patients with advanced nonsquamous non–small cell lung cancer (NSCLC) with...
Edoxaban Taken for 12 Months May Improve Outcomes in Patients With Cancer and Isolated Distal Deep Vein Thrombosis
Researchers have found that 12 months of the oral factor Xa inhibitor edoxaban may be superior to 3 months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis, according to new findings presented by Yamashita et al at the European Society of Cardiology...
How Is Administrative Payment Burden Associated With Cost-Related Delays in Cancer Care?
Research shows that the United States’ health-care delivery and financing system is so complex that streamlining administrative costs alone could reduce total health-care spending by 15%. In addition, health insurance payment and medical billing processes are time-consuming and expensive for both...
Urothelial Carcinoma: Perioperative PD-L1 Inhibition Plus Neoadjuvant Chemotherapy
In a Swiss phase II study (SAKK 06/17) reported in the Journal of Clinical Oncology, Richard Cathomas, MD, and colleagues found that the addition of perioperative durvalumab to neoadjuvant chemotherapy resulted in improved event-free and overall survival in patients with muscle-invasive urothelial...
ER-Positive Breast Cancer: Addition of Adjuvant Ovarian Function Suppression to Tamoxifen in Premenopausal Patients
In an 8-year follow-up of a Korean phase III trial (ASTRRA) reported in the Journal of Clinical Oncology, Baek et al evaluated the effects of adding adjuvant ovarian function suppression to tamoxifen in premenopausal patients with estrogen receptor (ER)-positive breast cancer, with a focus on the...
Are Cannabinoids Safe and Effective for Reducing Symptoms in Pediatric Patients With Cancer?
Investigators have revealed that there may be a lack of evidence to inform the dosing, safety, and efficacy of cannabinoids for managing symptoms in pediatric patients with cancer, according to a recent systematic review and meta-analysis published by Chhabra et al in Cancer. Background Although...
Optimizing Tobacco Cessation Treatment With Lung Cancer Screenings
The Program for Lung Cancer Screening and Tobacco Cessation trial tested different adaptive interventions based on the evidence-based Tobacco Longitudinal Care (TLC) program, in part to learn how best to incorporate TLC into annual lung cancer screening as a smoking cessation standard. The findings ...
